AU2021218735A1 - Method of decreasing amyloid beta monomer levels in patients with cognitive decline - Google Patents
Method of decreasing amyloid beta monomer levels in patients with cognitive decline Download PDFInfo
- Publication number
- AU2021218735A1 AU2021218735A1 AU2021218735A AU2021218735A AU2021218735A1 AU 2021218735 A1 AU2021218735 A1 AU 2021218735A1 AU 2021218735 A AU2021218735 A AU 2021218735A AU 2021218735 A AU2021218735 A AU 2021218735A AU 2021218735 A1 AU2021218735 A1 AU 2021218735A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- amyloid
- months
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976325P | 2020-02-13 | 2020-02-13 | |
| US62/976,325 | 2020-02-13 | ||
| PCT/US2021/018023 WO2021163613A1 (en) | 2020-02-13 | 2021-02-12 | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021218735A1 true AU2021218735A1 (en) | 2022-09-01 |
Family
ID=77292728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021218735A Pending AU2021218735A1 (en) | 2020-02-13 | 2021-02-12 | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230098944A1 (https=) |
| EP (1) | EP4103604A4 (https=) |
| JP (2) | JP2023513220A (https=) |
| KR (1) | KR20220142477A (https=) |
| CN (1) | CN115397849A (https=) |
| AU (1) | AU2021218735A1 (https=) |
| IL (1) | IL295427A (https=) |
| WO (1) | WO2021163613A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2692258C2 (ru) | 2014-01-31 | 2019-06-24 | Когнишн Терапьютикс, Инк. | Композиции изоиндолина и способы лечения нейродегенеративного заболевания |
| WO2024196799A2 (en) * | 2023-03-17 | 2024-09-26 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026030341A1 (en) * | 2024-07-29 | 2026-02-05 | Cognition Therapeutics, Inc. | Zervimesine for treating neurodegenerative disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753662A (zh) * | 2002-12-24 | 2006-03-29 | 神经化学（国际）有限公司 | 用于治疗β－淀粉状蛋白相关疾病的治疗制剂 |
| CA2611586A1 (en) * | 2005-04-12 | 2007-06-21 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| RU2692258C2 (ru) * | 2014-01-31 | 2019-06-24 | Когнишн Терапьютикс, Инк. | Композиции изоиндолина и способы лечения нейродегенеративного заболевания |
| WO2018156883A1 (en) * | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| AU2019318888A1 (en) * | 2018-08-07 | 2021-03-18 | Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
-
2021
- 2021-02-12 AU AU2021218735A patent/AU2021218735A1/en active Pending
- 2021-02-12 US US17/798,667 patent/US20230098944A1/en active Pending
- 2021-02-12 KR KR1020227031662A patent/KR20220142477A/ko active Pending
- 2021-02-12 CN CN202180027929.1A patent/CN115397849A/zh active Pending
- 2021-02-12 EP EP21754581.3A patent/EP4103604A4/en active Pending
- 2021-02-12 WO PCT/US2021/018023 patent/WO2021163613A1/en not_active Ceased
- 2021-02-12 JP JP2022548088A patent/JP2023513220A/ja active Pending
- 2021-02-12 IL IL295427A patent/IL295427A/en unknown
-
2025
- 2025-11-24 JP JP2025202377A patent/JP2026041805A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115397849A (zh) | 2022-11-25 |
| US20230098944A1 (en) | 2023-03-30 |
| JP2026041805A (ja) | 2026-03-10 |
| WO2021163613A1 (en) | 2021-08-19 |
| JP2023513220A (ja) | 2023-03-30 |
| EP4103604A1 (en) | 2022-12-21 |
| IL295427A (en) | 2022-10-01 |
| KR20220142477A (ko) | 2022-10-21 |
| EP4103604A4 (en) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021218735A1 (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
| JP4767982B2 (ja) | 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用 | |
| KR20220139414A (ko) | 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물 | |
| KR20190126365A (ko) | 마우스 근시 유도 모델 및 근시 예방·억제를 위한 소포체 스트레스 억제제 | |
| KR20160067103A (ko) | 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물 | |
| KR20140041457A (ko) | 신경 장애 치료용 신규 조성물 | |
| CA3005887A1 (en) | Methods for treating alzheimer's disease and related disorders | |
| JP2013533310A (ja) | 苦味物質を使用して閉塞性肺疾患を処置する方法 | |
| EP3813816B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| CN113710242A (zh) | 用于治疗神经变性障碍的组合物和方法 | |
| CA3154744A1 (en) | Glp-1 receptor agonists in dementia | |
| JP2012500801A (ja) | Ｃｎｓ疾患の治療法 | |
| CN110300581A (zh) | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 | |
| RU2841658C1 (ru) | Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей | |
| RU2722272C1 (ru) | Средство для лечения и профилактики нематодозов и цестодозов у мелких домашних животных | |
| HK40083593A (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
| JP2011520881A (ja) | 認知機能を改善するための方法および組成物 | |
| US12311005B2 (en) | Pharmaceutical compositions and uses thereof in treating Parkinson's disease | |
| US20220133702A1 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| WO2005082351A1 (ja) | 神経変性疾患治療剤 | |
| CN120305240A (zh) | 4-羟基扁桃酸类化合物用于制备预防或治疗阿尔茨海默病的药物的用途 | |
| WO2026052068A1 (zh) | 药物组合物的用途 | |
| CN117942336A (zh) | Go6976在用于制备抗抑郁药物中的应用 | |
| CN120459095A (zh) | 氨基吡啶类物质抑制α-突触核蛋白聚集和路易小体形成的用途 | |
| CN118574810A (zh) | 用尼罗加司他治疗卵巢癌 |